Kolexia
Park Sophie Hématologie
Park Sophie
Hématologie
Hôpital Nord Grenoble
La Tronche, France
293 Activités
460 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Leucémie myélomonocytaire chronique Leucémie aigüe myéloïde Préleucémie Leucémie myéloïde Anémie Carcinomes Lymphomes

Collaborateurs

Voir plus
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France
Ades Lionel
Ades Lionel
Hôpital Saint-Louis, Paris, France
Rauzy Odile
Rauzy Odile
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Novartis
24 collaboration(s)
Dernière en 2023
Pfizer
13 collaboration(s)
Dernière en 2023
BMS
7 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
7 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
MPO-MDS-Develp: Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.
Essai Clinique (CHU Grenoble)   18 mars 2024
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Essai Clinique (Syros Pharmaceuticals)   11 mars 2024
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia   17 février 2024
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes
65th ASH Annual Meeting Abstracts   02 novembre 2023
FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms
65th ASH Annual Meeting Abstracts   02 novembre 2023
208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations
Abstract Book of the ESMO Asia Congress 2023, 1-3 December 2023   01 novembre 2023